CLOs on the Move

Bibb Med Center Hospital and Nh

www.bibbmedicalcenter.com

 
Bibb Med Center Hospital & Nh is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Centreville, AL. To find more information about Bibb Med Center Hospital & Nh, please visit www.bibbmedicalcenter.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Carolinas Shared Services

Carolinas Shared Services is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lumosity

Lumosity is an online program consisting of games claiming to improve memory, attention, flexibility, speed of processing, and problem solving.

BZAM Cannabis

Headquartered in Vancouver, BC, BZAM Cannabis is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people.

Complete Medical Communications

Complete Medical Communications is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.